The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index; 71 of the 128 sources its claims cite were checked for support.
Irritable bowel syndrome
Abstract
Irritable bowel syndrome is a functional gastrointestinal disorder with symptoms including abdominal pain associated with a change in stool form or frequency. The condition affects between 5% and 10% of otherwise healthy individuals at any one point in time and, in most people, runs a relapsing and remitting course. The best described risk factor is acute enteric infection, but irritable bowel syndrome is also more common in people with psychological comorbidity and in young adult women than in the rest of the general population. The pathophysiology of irritable bowel syndrome is incompletely understood, but it is well established that there is disordered communication between the gut and the brain, leading to motility disturbances, visceral hypersensitivity, and altered CNS processing. Other less reproducible mechanisms might include genetic associations, alterations in gastrointestinal microbiota, and disturbances in mucosal and immune function. In most people, diagnosis can be made on the basis of clinical history with limited and judicious use of investigations, unless alarm symptoms such as weight loss or rectal bleeding are present, or there is a family history of inflammatory bowel disease or coeliac disease. Once the diagnosis is made, an empathetic approach is key and can improve quality of life and symptoms, and reduce health-care expenditure. The mainstays of treatment include patient education about the condition, dietary changes, soluble fibre, and antispasmodic drugs. Other treatments tend to be reserved for people with severe symptoms and include central neuromodulators, intestinal secretagogues, drugs acting on opioid or 5-HT receptors, or minimally absorbed antibiotics (all of which are selected according to predominant bowel habit), as well as psychological therapies. Increased understanding of the pathophysiology of irritable bowel syndrome in the past 10 years has led to a healthy pipeline of novel drugs in development.
Overview
CoChat Summary
TL;DR
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterised by recurrent abdominal pain associated with altered stool form or frequency, affecting 5–10% of otherwise healthy individuals in the community at any one time. Management centres on an empathetic clinical diagnosis with limited investigations, first-line dietary and antispasmodic therapies, and second-line central neuromodulators, secretagogues, 5-HT/opioid-targeted drugs, antibiotics, or psychological therapies for more severe symptoms.
Key findings
- Global prevalence is commonly estimated at 5–10%, but Rome Foundation 33-nation data using Rome IV criteria found prevalence rates of 2–6%, with a pooled prevalence of 4.1%; where both Rome III and IV were applied, pooled prevalence fell from 10.1% with Rome III to 3.8% with Rome IV.
- Prior acute enteric infection is the best-recognised risk factor, observed in approximately 10% of patients; a meta-analysis of 45 observational studies reported a four-fold increase in odds of IBS 12 months post-infection (OR 4.2; 95% CI 3.1 to 5.7).
- In treatment meta-analyses, antispasmodics reduced the risk of remaining symptomatic versus placebo (RR 0.65; 95% CI 0.56 to 0.76) but increased side effects (RR 1.60; 95% CI 1.15 to 2.21); TCAs reduced remaining symptomatic (RR 0.65; 95% CI 0.55 to 0.77) with more adverse events (RR 1.56; 95% CI 1.23 to 1.98); ispaghula husk (RR 0.83; 95% CI 0.73 to 0.94) and peppermint oil (RR 0.54; 95% CI 0.39 to 0.76) were also superior to placebo.
- Annual direct and indirect IBS-related costs are estimated at up to €8 billion in Europe, ¥123 billion in China, and in excess of $10 billion in the USA.
Methods
- Narrative review with a stated search of MEDLINE, EMBASE, EMBASE Classic, and the Cochrane Central Register of Controlled Trials over the last 10 years, plus clinicaltrials.gov for unpublished trials, using terms including “irritable bowel syndrome”, “epidemiology”, “pathophysiology”, “diagnosis”, “management”, and “treatment”.
- Included only English-language publications, selecting articles judged by the authors to be of greatest importance and favouring randomised controlled trials, meta-analyses, and network meta-analyses.
- Evidence is synthesised narratively across epidemiology, risk factors, pathophysiology, diagnosis, investigations, natural history, and management.
Limitations
- The paper states that methodological limitations make reliable prevalence estimates difficult, that most risk-factor studies are cross-sectional and lack the temporal element needed to determine cause and effect, and that no universally accepted biomarker for IBS exists.
- It also states that many first-line drug RCTs are old, have suboptimal methodology and heterogeneous patient selection, and use efficacy endpoints that do not meet current FDA or EMA recommendations; most RCTs are only 12 weeks, so long-term efficacy is unknown.
- Evident from the text: this is a narrative review, not a systematic review, with article selection based on the authors’ view, English-language restriction, and a 10-year search window; no formal risk-of-bias assessment or PRISMA-style protocol is reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
48 Valid · 17 Not valid · 45 Not checked · 39 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The addition of other features from the clinical history, including absence of nocturnal stools, presence of anxiety, depression, or extra-intestinal symptoms, and a normal full blood count and C-reactive protein enhances the diagnostic performance of the Rome III criteria. 69”
What the sources say
- Disputedcites [69] Kane, 2015, Development and validation of a scoring system to identify patients with microscopic colitis, Clin Gastroenterol Hepatol sourceExperimental — accuracy not yet measured
The Derivation cohort (p. 11) reports that nocturnal diarrhea was not significantly associated with microscopic colitis and did not contribute to the paper’s diagnostic score, contrary to the claimed benefit of adding absence of nocturnal stools. The Discussion (p. 14) describes a different score based on age, gender, medication use, weight loss, and abdominal pain; it does not assess additions to the Rome III criteria. (LLM, conf=0.83)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“In addition to the psychological component of IBS, 22 gut-brain communication is bidirectional.”
What the sources say
- Could not verifycites [22] Zheng, 2020, Reduced efficacy of low FODMAPs diet in patients with IBS-D carrying sucrase-isomaltase (SI) hypomorphic variants, Gut sourceExperimental — accuracy not yet measured
The paper’s main text (page not provided) discusses sucrase-isomaltase variants, carbohydrate malabsorption, and dietary response in IBS-D. Searches for bidirectional gut-brain communication and the brain–gut axis found no passage addressing the claim. (LLM, conf=0.76)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In two systematic reviews, rates of IBS were significantly higher in females 4,13”
What the sources say
- Not checked — no full text of the sourcecites [4] Sperber, 2017, The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review, Gut source
- Partly supportedcites [13] Sperber, 2020, Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study, Gastroenterology sourceExperimental — accuracy not yet measured
The Functional bowel disorders section reports substantially higher pooled IBS prevalence among women, with female-to-male odds ratios whose confidence intervals exclude 1. However, the Methods describe this paper as a multinational survey, not a systematic review, so the citing sentence mischaracterizes the type of evidence it provides. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Perhaps the best-recognised risk factor for IBS, observed in approximately 10% of patients, 17 is prior acute enteric infection.”
What the sources say
- Supportedcites [17] Card, 2018, Post-infectious IBS: defining its clinical features and prognosis using an internet-based survey, United European Gastroenterol J source
The Diagnosis of PI-IBS section reports that 1004 of 7552 IBS cases (13.3%) were post-infectious, consistent with approximately 10% of patients. The Introduction describes IBS developing after acute infection, and the paper calls gastrointestinal infection an important risk factor. Its separate 10.1% figure is the incidence of new IBS after infection, not the proportion of IBS patients with a prior infection. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This is termed post-infection IBS (PI-IBS), and can occur after bacterial, viral, or protozoal infection. 18”
What the sources say
- Supportedcites [18] Klem, 2017, Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis, Gastroenterology source
The Introduction explicitly states that bacterial, viral, and protozoal enteritis have all been associated with the development of post-infectious IBS. The Discussion also reports PI-IBS following each type of enteritis. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
92 more claims · 33 with their cited sources checked
Create a free account to see all 149 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 15
- It may state two separate claims as one. 43
- The quote only partly states this claim. 1
Citations
Cites
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
Sperber, A. D., Bangdiwala, S. I., Drossman, D. A., Ghoshal, U. C., Simren, M., Tack, J., Whitehead, W. E., Dumitrascu, D. L., Fang, X., Fukudo, S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.04.014 · Cited by 2,263
Self-citationGlobal Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
Self-citationPeery, A. F., Crockett, S. D., Murphy, C. C., Lund, J. L., Dellon, E. S., Williams, J. L., Jensen, E. T., Shaheen, N. J., Barritt, A. S., Lieber, S. R., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.08.063 · Cited by 1,619
A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome
Halmos, E. P., Power, V. A., Shepherd, S. J., Gibson, P. R., & Muir, J. G. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.09.046 · Cited by 1,249
Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome
Ritchie, J. (1973) · Gut · doi:10.1136/gut.14.2.125 · Cited by 832
Eradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome
Pimentel, M., Chow, E. J., & Lin, H. C. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03368.x · Cited by 780
Gut Microbiota in Patients With Irritable Bowel Syndrome—A Systematic Review
Pittayanon, R., Lau, J. T., Yuan, Y., Leontiadis, G. I., Tse, F., Surette, M., & Moayyedi, P. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.03.049 · Cited by 719
Diets that differ in their FODMAP content alter the colonic luminal microenvironment
Halmos, E. P., Christophersen, C. T., Bird, A. R., Shepherd, S. J., Gibson, P. R., & Muir, J. G. (2015) · Gut · doi:10.1136/gutjnl-2014-307264 · Cited by 681
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Aburto, M. R., & Cryan, J. F. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00890-0 · Cited by 359
Black, C. J., Staudacher, H. M., & Ford, A. C. (2022) · Gut · doi:10.1136/gutjnl-2021-325214 · Cited by 353
Self-citationThe neurobiology of irritable bowel syndrome
Mayer, E. A., Ryu, H. J., & Bhatt, R. R. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01972-w · Cited by 257
The enteric nervous system in gastrointestinal disease etiology
Holland, A. M., Bon-Frauches, A. C., Keszthelyi, D., Melotte, V., & Boesmans, W. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03812-y · Cited by 161
Metadata
- Authors
- Ford, A. C., Sperber, A. D., Corsetti, M., & Camilleri, M.
- Affiliations
- University of Leeds (GB)
- Ben-Gurion University of the Negev (IL)
- Nottingham University Hospitals NHS Trust (GB)
- Mayo Clinic (US)
- Corresponding author
- Ford, Alexander C
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 396
- Issue
- 10263
- Pages
- 1675-1688
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4296277377
- Cited by
- 818
- References
- 147
- Citations by year
- 2026: 152 · 2025: 150 · 2024: 147 · 2023: 158 · 2022: 136 · 2021: 74
- FWCI
- 16.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- irritable bowel syndrome, functional gastrointestinal disorders, gut-brain axis, visceral hypersensitivity, bowel motility disorders, acute intestinal infections, psychological comorbidity, risk factors, diagnosis, patient education, dietary fiber, antispasmodic agents, neuromodulators, serotonin receptor agonists, opioid antagonists, psychotherapy, quality of life, new drug development
- MeSH terms
- Gastrointestinal Microbiome, Brain, Dietary Fiber, Gastrointestinal Agents, Gastrointestinal Diseases, Humans, Quality of Life, Abdominal Pain, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Irritable bowel syndrome. https://app.cochat.ai/papers/10.1016/s0140-6736(20)31548-8
- The paper
- Ford, A. C., Sperber, A. D., Corsetti, M., & Camilleri, M. (2020). Irritable bowel syndrome. The Lancet. https://doi.org/10.1016/s0140-6736(20)31548-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.